With 0.94 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.6 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $137.21 whereas the lowest price it dropped to was $134.12. The 52-week range on A shows that it touched its highest point at $151.58 and its lowest point at $96.80 during that stretch. It currently has a 1-year price target of $150.54. With its current market cap of 39.96 billion, A has annualized dividend of $0.92 while the current yield stands at 0.68%. Beta for the stock currently stands at 1.13.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of A was up-trending over the past week, with a rise of 2.97%, but this was down by -5.57% over a month. Three-month performance surged to 5.00% while six-month performance rose 29.09%. The stock gained 4.60% in the past year, while it has lost -1.91% so far this year. A look at the trailing 12-month EPS for A yields 4.20 with Next year EPS estimates of 6.11. For the next quarter, that number is 1.19. This implies an EPS growth rate of 1.15% for this year and 10.95% for next year. EPS is expected to grow by 8.05% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 33.93%.
Float and Shares Shorts:
At present, 292.12 million A shares are outstanding with a float of 291.84 million shares on hand for trading. On 2024-04-15, short shares totaled 4.12 million, which was 140.99999 higher than short shares on 1710460800. In addition to Mr. Michael R. McMullen as the firm’s CEO, President & Director, Mr. Robert W. McMahon serves as its Senior VP, CFO and Interim President of Diagnostics & Genomics Group.
Institutional Ownership:
Through their ownership of 0.92751 of A’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-01-31, A reported revenue of $1658000000.0 and operating income of $384000000.0. The EBITDA in the recently reported quarter was $487000000.0 and diluted EPS was $1.18.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for A since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
